• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Blackstone Life Sciences and Anthos Therapeutics Announce Novartis has Completed the Acquisition of Anthos Therapeutics in a Deal Valued at up to $3.1B, with $925M Paid Upfront

    4/3/25 4:15:00 PM ET
    $BX
    Investment Managers
    Finance
    Get the next $BX alert in real time by email

    The deal affirms Blackstone's vision of building companies around innovative products to meet unmet patient needs

    Blackstone Life Sciences and Anthos Therapeutics, Inc., a transformative, clinical-stage biopharmaceutical company developing innovative therapies for the treatment of cardiometabolic diseases, announced today that Novartis has completed its acquisition of Anthos Therapeutics in a transaction valued at up to $3.1 billion.

    Anthos was founded by Blackstone Life Sciences and Novartis in 2019 with the exclusive global rights from Novartis to develop, manufacture, and commercialize abelacimab, a novel Factor XI inhibitor that originated at Novartis. Abelacimab is currently in Phase 3 clinical development for the prevention of stroke and systemic embolism in patients with atrial fibrillation (LILAC-TIMI 76), in addition to two phase 3 studies in patients with cancer-associated thrombosis (ASTER and MAGNOLIA). Data from these trials are expected in the second half of 2026.

    Transaction Details

    Anthos shareholders will receive up to $3.1 billion in total deal value, including an upfront payment of $925 million, and payments in the event certain regulatory and commercial milestones are achieved.

    Advisors

    Goldman Sachs & Co. LLC acted as the lead financial advisor to Anthos. Morgan Stanley & Co. LLC also served as a financial advisor, and Goodwin Procter LLP served as legal advisor to Anthos.

    About Blackstone Life Sciences

    Blackstone Life Sciences (BXLS) is an industry-leading private investment platform with capabilities to invest across the life cycle of companies and products within the key life science sectors. By combining scale investments and hands-on operational leadership, BXLS helps bring to market promising new medicines and medical technologies that improve patients' lives and currently has $12 billion in assets under management.

    About Anthos Therapeutics

    Founded by BXLS in 2019, Anthos Therapeutics is a transformative, clinical-stage biopharmaceutical company with exclusive global rights from Novartis Pharma AG to develop, manufacture and commercialize abelacimab. BXLS was the majority investor in the company, joined by other partners including Novo Holdings. For more information about Anthos, visit the Company's website.

    About Abelacimab

    Abelacimab is a novel, investigational, highly selective, fully human monoclonal antibody that binds tightly to Factor XI to block its activation and prevent the generation of the activated form (Factor XIa). This mimics natural Factor XI deficiency, which is associated with protection from thromboembolic disease.

    Abelacimab received a Fast Track Designation from the FDA in July 2022 for the treatment of thrombosis associated with cancer. In September 2022, abelacimab was also granted a Fast Track Designation for the prevention of stroke and systemic embolism in patients with atrial fibrillation.

    Forward-Looking Statements

    This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties, including statements regarding the expected benefits of Novartis' acquisition of Anthos, future opportunities for the combined businesses, the development and commercialization of Anthos Therapeutics' product candidates and the potential benefits of abelacimab. All statements, other than statements of historical facts, contained in this press release, including statements regarding the company's strategy, future operations, future financial position, prospects, plans and objectives of management, are forward-looking statements. The words "anticipate," "become," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in, or implied by, such forward-looking statements. Actual results may differ materially because of numerous risks and uncertainties including with respect to (i) the risk that the expected benefits or synergies of the acquisition will not be realized and (ii) the risk that the milestones may not be achieved and resulting payments may not be realized, and (iii) unanticipated impact of the acquisition, including the response of business partners and competitors to the announcement of the acquisition or difficulties in employee retention. The actual financial impact of this transaction may differ from the expected financial impact described in this press release. In addition, the product candidate described in this press release is subject to all the risks inherent in the drug development process, and there can be no assurance that its development will be commercially successful. No forward-looking statement can be guaranteed. In addition, the forward-looking statements included in this press release represent the company's views as of the date hereof and should not be relied upon as representing the company's views as of any date subsequent to the date hereof. The company anticipates that subsequent events and developments will cause the company's views to change. However, while the company may elect to update these forward-looking statements at some point in the future, the company specifically disclaims any obligation to do so.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250403148958/en/

    Media

    Blackstone

    Paula Chirhart

    [email protected]

    Get the next $BX alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $BX

    DatePrice TargetRatingAnalyst
    4/8/2025$165.00Mkt Perform → Mkt Outperform
    Citizens JMP
    3/17/2025$180.00Neutral → Buy
    UBS
    12/12/2024$188.00 → $195.00Overweight → Equal Weight
    Wells Fargo
    12/9/2024$149.00 → $230.00Hold → Buy
    TD Cowen
    10/9/2024$149.00Overweight → Neutral
    Piper Sandler
    9/12/2024$163.00Overweight
    Wells Fargo
    8/27/2024$134.00Neutral
    Redburn Atlantic
    4/2/2024$140.00 → $135.00Buy → Neutral
    UBS
    More analyst ratings

    $BX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Blackstone Makes a Significant Growth Investment into NetBrain to Rapidly Expand Network Automation and AI Solutions to Global Enterprises at a $750M Valuation

      Investment Seeks to Accelerate Adoption of AI in the $30 Billion Networking Operations (NetOps) Solutions Market Blackstone (NYSE:BX) announced today that Blackstone Growth (BXG) and affiliated funds (collectively "Blackstone") have entered into a definitive agreement to make a majority growth investment in NetBrain Technologies, a market-leading Network Automation and AI platform. The investment, which values NetBrain at $750 million, is intended to enable the company to accelerate innovation, expand its global footprint, and scale its AI-powered platform to meet the rising demand for intelligent network automation solutions. NetBrain is the market leader in network automation and AI,

      7/22/25 9:00:00 AM ET
      $BX
      Investment Managers
      Finance
    • Blackstone to Invest More Than $25 Billion in Pennsylvania's Digital and Energy Infrastructure, Plus Catalyze an Additional $60 Billion Investment

      Pennsylvania is uniquely suited to serve as a strategic hub to power America's AI future Blackstone-backed QTS, the largest independent data center operator in the world, to develop and operate new Pennsylvania data center sites Blackstone has formed a joint venture with PPL to invest in new Pennsylvania natural gas power generation facilities Over 6,000 jobs will be created or supported annually over an estimated 10-year construction timeline Blackstone (NYSE:BX) announced today that funds managed by Blackstone Infrastructure and Blackstone Real Estate ("Blackstone") will invest over $25 billion to support the build out of Pennsylvania's digital and energy infrastructure and h

      7/15/25 2:26:00 PM ET
      $BX
      Investment Managers
      Finance
    • Blackstone Multi-Asset Investing (BXMA) Hires Monica Issar as Senior Managing Director

      Blackstone (NYSE:BX) today announced that Monica Issar will join Blackstone Multi-Asset Investing ("BXMA") as a Senior Managing Director based in New York where she will be the Head of Total Portfolio Management ("TPM"). Monica will join the TPM leadership team partnering closely with Co-Chief Investment Officers, Joe Dowling and David Ben-Ur. She will report directly to Joe Dowling, Global Head of Blackstone Multi-Asset Investing. "Monica is a proven leader with a remarkable track record of driving innovation in investment solutions and scaling multi-asset platforms," says Joe Dowling. "Her expertise will be pivotal in advancing BXMA's portfolio management capabilities and delivering val

      7/14/25 4:05:00 PM ET
      $BX
      Investment Managers
      Finance

    $BX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Blackstone Holdings I L.P. bought $30,000,000 worth of Common Shares of Beneficial Interest (1,189,532 units at $25.22) (SEC Form 4)

      4 - Blackstone Inc. (0001393818) (Reporting)

      7/18/25 5:42:13 PM ET
      $BX
      Investment Managers
      Finance
    • Director Breyer James was granted 1,295 shares, increasing direct ownership by 3% to 41,836 units (SEC Form 4)

      4 - Blackstone Inc. (0001393818) (Issuer)

      7/15/25 5:16:08 PM ET
      $BX
      Investment Managers
      Finance
    • Director Lazarus Rochelle B was granted 1,334 shares, increasing direct ownership by 2% to 57,746 units (SEC Form 4)

      4 - Blackstone Inc. (0001393818) (Issuer)

      7/10/25 4:16:28 PM ET
      $BX
      Investment Managers
      Finance

    $BX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Blackstone upgraded by Citizens JMP with a new price target

      Citizens JMP upgraded Blackstone from Mkt Perform to Mkt Outperform and set a new price target of $165.00

      4/8/25 9:06:48 AM ET
      $BX
      Investment Managers
      Finance
    • Blackstone upgraded by UBS with a new price target

      UBS upgraded Blackstone from Neutral to Buy and set a new price target of $180.00

      3/17/25 7:24:34 AM ET
      $BX
      Investment Managers
      Finance
    • Blackstone downgraded by Wells Fargo with a new price target

      Wells Fargo downgraded Blackstone from Overweight to Equal Weight and set a new price target of $195.00 from $188.00 previously

      12/12/24 7:26:35 AM ET
      $BX
      Investment Managers
      Finance

    $BX
    SEC Filings

    See more
    • SEC Form 8-K filed by Blackstone Inc.

      8-K - Blackstone Inc. (0001393818) (Filer)

      7/24/25 6:55:31 AM ET
      $BX
      Investment Managers
      Finance
    • Blackstone Inc. filed SEC Form 8-K: Regulation FD Disclosure

      8-K - Blackstone Inc. (0001393818) (Filer)

      6/24/25 4:48:40 PM ET
      $BX
      Investment Managers
      Finance
    • SEC Form 144 filed by Blackstone Inc.

      144 - Blackstone Inc. (0001393818) (Subject)

      6/23/25 4:44:17 PM ET
      $BX
      Investment Managers
      Finance

    $BX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Blackstone Holdings I L.P. bought $30,000,000 worth of Common Shares of Beneficial Interest (1,189,532 units at $25.22) (SEC Form 4)

      4 - Blackstone Inc. (0001393818) (Reporting)

      7/18/25 5:42:13 PM ET
      $BX
      Investment Managers
      Finance
    • Director Porat Ruth bought $40,342 worth of shares (296 units at $136.49), increasing direct ownership by 0.64% to 37,067 units (SEC Form 4)

      4 - Blackstone Inc. (0001393818) (Issuer)

      5/6/25 5:22:40 PM ET
      $BX
      Investment Managers
      Finance
    • Adviser Blackstone Private Credit Strategies Llc bought $24,900,000 worth of Class I Common Shares of Beneficial Interest (1,660,000 units at $15.00) (SEC Form 4)

      4 - Blackstone Inc. (0001393818) (Reporting)

      5/2/25 4:30:24 PM ET
      $BX
      Investment Managers
      Finance

    $BX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Blackstone Inc.

      SC 13G - Blackstone Inc. (0001393818) (Subject)

      11/13/24 3:07:30 PM ET
      $BX
      Investment Managers
      Finance
    • SEC Form SC 13G/A filed by Blackstone Inc. (Amendment)

      SC 13G/A - Blackstone Inc. (0001393818) (Subject)

      2/13/24 4:55:49 PM ET
      $BX
      Investment Managers
      Finance
    • SEC Form SC 13G filed by Blackstone Inc.

      SC 13G - Blackstone Inc. (0001393818) (Subject)

      1/29/24 3:26:26 PM ET
      $BX
      Investment Managers
      Finance

    $BX
    Financials

    Live finance-specific insights

    See more
    • Blackstone Life Sciences and Anthos Therapeutics Announce Novartis has Completed the Acquisition of Anthos Therapeutics in a Deal Valued at up to $3.1B, with $925M Paid Upfront

      The deal affirms Blackstone's vision of building companies around innovative products to meet unmet patient needs Blackstone Life Sciences and Anthos Therapeutics, Inc., a transformative, clinical-stage biopharmaceutical company developing innovative therapies for the treatment of cardiometabolic diseases, announced today that Novartis has completed its acquisition of Anthos Therapeutics in a transaction valued at up to $3.1 billion. Anthos was founded by Blackstone Life Sciences and Novartis in 2019 with the exclusive global rights from Novartis to develop, manufacture, and commercialize abelacimab, a novel Factor XI inhibitor that originated at Novartis. Abelacimab is currently in Phase

      4/3/25 4:15:00 PM ET
      $BX
      Investment Managers
      Finance
    • Blackstone Acquires Majority Stake in Leading Hotel Accounting Software and Services Provider M3

      Growth investment made in partnership with Asian American Hotel Owners Association (AAHOA) M3, LLC ("M3"), voted the number-one hospitality accounting software in North America, today announced it has signed a definitive agreement for a majority investment from Blackstone Growth and affiliated funds (collectively "Blackstone"). The investment will help to accelerate the company's growth by enhancing new product expansion and supporting the adoption of M3's software, which enables hotel operators to run more efficiently and effectively. AAHOA, representing nearly 20,000 hotel owners and 60% of hotels across the United States, will make its first ever strategic investment alongside Blacksto

      8/15/24 9:00:00 AM ET
      $BX
      Investment Managers
      Finance
    • Blackstone Completes Acquisition of Tropical Smoothie Cafe

      Blackstone (NYSE:BX) announced today that private equity funds managed by Blackstone ("Blackstone") have completed the acquisition of Tropical Smoothie Cafe, a leading franchisor of fast casual restaurants, from Levine Leichtman Capital Partners. This marks the first transaction in Blackstone's most recent vintage of its flagship private equity vehicle. "Tropical Smoothie Cafe is a nationally recognized brand with an impressive growth trajectory underpinned by a base of loyal franchisees and guests," said Peter Wallace, a Senior Managing Director, and Michael Staub, a Managing Director, in Blackstone's Private Equity business. "With Blackstone's capital and resources, we look forward to a

      6/10/24 10:30:00 AM ET
      $BX
      Investment Managers
      Finance

    $BX
    Leadership Updates

    Live Leadership Updates

    See more
    • Blackstone Multi-Asset Investing (BXMA) Hires Monica Issar as Senior Managing Director

      Blackstone (NYSE:BX) today announced that Monica Issar will join Blackstone Multi-Asset Investing ("BXMA") as a Senior Managing Director based in New York where she will be the Head of Total Portfolio Management ("TPM"). Monica will join the TPM leadership team partnering closely with Co-Chief Investment Officers, Joe Dowling and David Ben-Ur. She will report directly to Joe Dowling, Global Head of Blackstone Multi-Asset Investing. "Monica is a proven leader with a remarkable track record of driving innovation in investment solutions and scaling multi-asset platforms," says Joe Dowling. "Her expertise will be pivotal in advancing BXMA's portfolio management capabilities and delivering val

      7/14/25 4:05:00 PM ET
      $BX
      Investment Managers
      Finance
    • Blackstone Tactical Opportunities Hires Joseph Cassanelli as Senior Managing Director Focused on Financial Services Sector Investments

      Blackstone (NYSE:BX) announced today that Joseph Cassanelli, former Co-Head of Lazard's U.S. Financial Institutions Group, has joined Blackstone Tactical Opportunities ("Tac Opps") as a Senior Managing Director. Mr. Cassanelli will be based in New York and serve as an investment professional within Tac Opps focused on the financial services sector. Chris James, Global Head of Tac Opps, said: "Joe's deep expertise and relationships in the financial services sector make him an ideal addition to Tac Opps – as we continue to seek to deliver differentiated performance for our investors. We believe our scale and flexible capital are particularly well suited for today's market environment, and l

      6/16/25 10:30:00 AM ET
      $BX
      Investment Managers
      Finance
    • Wellington, Vanguard, and Blackstone to Collaborate on Investment Solutions Combining Public and Private Assets

      Wellington Management ("Wellington"), Vanguard, and Blackstone (NYSE:BX) today announced a strategic alliance to transform how investors access institutional-caliber investment opportunities. The three firms will collaborate on developing simplified multi-asset investment solutions that seamlessly integrate public and private markets as well as active and index strategies. The collaboration seeks to broaden access to sophisticated multi-asset portfolios ordinarily available to the largest global institutions. The new initiative, which is the first of its kind for the firms, brings together three world-class organizations drawing on their respective strengths: Wellington's nearly 100-year

      4/15/25 9:00:00 AM ET
      $BX
      Investment Managers
      Finance